Login
$ARWR
$44.25 +$0.04 (0.09%) After hours

$ARWR 8-K/A SEC Filings

Filed On Filing
18 Mar 2024 8-K/A: Departure/Election of Directors or Officers; Compensation

On March 14, 2024, the Board approved an amendment to the effective date of (i) Dr. Lu’s appointment to the Board and (ii) the increase in size of the Board from seven to eight members, each to be effective as of March 15, 2024 ("Amended...

30 Dec 2011 8-K/A: Financial Statements and Exhibits

Balance Sheet as of September 30, 2011 and December 31, 2010

21 Jul 2009 8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On July 17, 2009, Arrowhead Research Corporation (the “Company”) fully executed definitive agreements for a private placement offering (the “Offering”) with selected institutional and accredited investors, which closed simultaneously. Pu...

23 Jun 2008 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
21 Mar 2008 8-K/A: Departure/Election of Directors or Officers; Compensation

Effective December 1, 2007, Dr. Christopher Anzalone (38 years old) was appointed Chief Executive Officer and President of the Company and elected to the Company’s Board of Directors. The Company’s Current Report on Form 8-K filed with t...

13 Mar 2008 8-K/A: Other Events

This presentation contains forward-looking statements within the meaning of the

28 Jun 2007 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma combined financial information has been prepared to give effect to the acquisition of CNI by Arrowhead and the related financing activities.

30 May 2007 8-K/A: Unregistered Sales of Equity Securities

On May 29, 2007, Arrowhead Research Corporation (the “Company”) completed the closing of its $16,469,800 million private placement (the “Private Offering”) of an aggregate of 2,849,446 shares (the “Shares”) of the Company’s common stock,...

11 Aug 2004 8-K/A: Financial Statements and Exhibits

We have audited the accompanying balance sheets of Insert Therapeutics, Inc., as of December 31, 2003 and 2002, and the statements of operations and cash flows for the years then ended. These financial statements are the responsibility o...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support